This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hande, K. R. Articles by Rothenberg, M. L. Search for Related Content PubMed PubMed Citation Articles by Hande, K. R. Articles by Rothenberg, M. L.

The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study

Authors' Affiliations: ¹ Vanderbilt/Ingram Cancer Center, Nashville, Tennessee and ² Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Kenneth R. Hande, 777 Preston Research Building, Vanderbilt University School of Medicine, Nashville, TN 37232. Phone: 615-322-4967; Fax: 615-343-7602; E-mail: kenneth.r.hande{at}vanderbilt.edu.

Purpose: Microtubules play a critical role in many cellular functions, including cell division and mitosis. ABT-751 is a novel sulfonamide antimitotic that binds to the colchicine site on ß-tubulin that leads to a block in the cell cycle at the G₂M phase, resulting in cellular apoptosis. ABT-751 was investigated in this phase 1 trial designed to assess its maximum tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics.

Experimental Design: ABT-751 was administered on a daily (q.d.) or twice daily (b.i.d.) oral schedule for 7 days every 3 weeks to 39 patients with refractory solid tumors. Toxicity was monitored weekly. Plasma and urine ABT-751 and metabolite pharmacokinetics were determined.

Results: The MTD for the q.d. schedule was 250 mg/d. DLTs during cycle 1 were abdominal pain, constipation, and fatigue. The MTD on the b.i.d. schedule was 150 mg. Cycle 1 of therapy with the 175 mg b.i.d. schedule was tolerated without DLT. However, six of seven patients reported grade 3 toxicity (ileus, constipation, abdominal pain, or fatigue), which occurred in cycle 2 or 3. ABT-751 was absorbed after oral administration with an overall mean T_max of about 2 hours. The pharmacokinetics of ABT-751 were dose-proportional and time-independent. There was minimal accumulation of ABT-751 after multiple q.d. and b.i.d. doses. Efficacious concentrations, as determined from preclinical models (0.5-1.5 µg/mL), were achieved in all subjects. ABT-751 metabolism occurred primarily by glucuronidation and sulfation. No complete or partial tumor responses were noted, but one patient had a minor response, and four patients had stable disease lasting at least 6 months.

Conclusions: The MTD and recommended phase 2 doses for ABT-751 were 250 mg q.d. and 150 mg b.i.d. on a 7-day schedule given every 3 weeks, due to subsequent cycle toxicities at 175 mg b.i.d. dosing. Toxicities were abdominal pain, constipation, and neuropathy.

This article has been cited by other articles:

				A.-M. Liberatore, H. Coulomb, D. Pons, O. Dutruel, P. G. Kasprzyk, M. Carlson, A. S. Nelson, S. P. Newman, C. Stengel, P. Auvray, et al. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents Mol. Cancer Ther., August 1, 2008; 7(8): 2426 - 2434. [Abstract] [Full Text] [PDF]

				E. Fox, J. M. Maris, B. C. Widemann, W. Goodspeed, A. Goodwin, M. Kromplewski, M. E. Fouts, D. Medina, S. L. Cohn, A. Krivoshik, et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1111 - 1115. [Abstract] [Full Text] [PDF]

				S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al. STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606. [Abstract] [Full Text] [PDF]